アナキンラ に 対する アレルギ を 克服 し た 子供 の 腸内 脱敏 療法 "症例 報告"
1Department of Pediatric Allergy and Clinical Immunology, The Royal Hospital, Muscat, Oman.
Case reports in immunology
|August 29, 2025
まとめ
腫瘍死因受容体関連周期性症候群 (TRAPS) とアナキナラ過敏症の患者を治療した. このアプローチにより,有害事象なしに治療を継続することができました.
科学分野:
- 免疫学
- 小児関節病学
背景:
- アナキンラ (再結合型インタールイキン-1受容体抗体) は,小児の自己炎症疾患の治療に不可欠です.
- アナキンラに対する過敏反応は,不敏感化戦略を必要とします.
- 針恐怖症は,子供にアナキナラ投与を複雑にすることがあります.
関連する概念動画
Desensitization and Tachyphylaxis
3.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.5K
Allergic Reactions: Anaphylaxis
210
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
210


